ProPhase Labs (NASDAQ:PRPH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a report released on Sunday morning. The firm issued a sell rating on the stock.

ProPhase Labs Trading Down 0.1 %

PRPH stock opened at $0.26 on Friday. ProPhase Labs has a 52 week low of $0.22 and a 52 week high of $7.48. The company has a market capitalization of $6.26 million, a PE ratio of -0.21 and a beta of -0.37. The company’s 50-day simple moving average is $0.58 and its 200 day simple moving average is $1.59. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.33 and a current ratio of 1.47.

Hedge Funds Weigh In On ProPhase Labs

Hedge funds have recently added to or reduced their stakes in the stock. HighTower Advisors LLC grew its holdings in shares of ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after purchasing an additional 57,736 shares in the last quarter. SVB Wealth LLC bought a new stake in ProPhase Labs during the fourth quarter worth about $36,000. Sheets Smith Wealth Management acquired a new stake in ProPhase Labs during the fourth quarter worth about $158,000. Finally, Geode Capital Management LLC increased its holdings in ProPhase Labs by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after buying an additional 13,590 shares during the period. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.